FDA Approves Belinostat for Peripheral T-Cell Lmphoma

The US Food and Drug Administration's approval comes by way of the agency's accelerated approval program.

Belinostat (Spectrum's Beleodaq) is a pan-histone deacetylase (HDAC) inhibitor. As a pan-histone inhibitor, this means it inhibits all three classes of zinc-dependent HDAC enzymes.

It has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), a very rare category of cancers that begin in the T cells of the immune system. About fifteen percent of the 70,000 new cases of non-Hodgkin's lymphoma each year are cases of PTCL.

"This is the third drug that has been approved since 2009 for the treatment of PTCL," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research. "Today's approval expands the number of treatment options available to patients with serious and life-threatening diseases."

Pazdur is referring to pralatrexate (Folotyn) and romidepsin (Istodax), both of which are approved to treat PTCL.

Belinostat's approval is based on a single-group clinical trial of just 129 people with relapsed or refractory PTCL. The overall response rate to the drug was 25.8 percent.

Source: FDA

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap